Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Tao Zhang
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07243938CT.gov Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | — | Not Yet Recruiting | — | — | — |
NCT06746545CT.gov A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer. | — | Not Yet Recruiting | — | — | — |
NCT03397199CT.gov Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer | — | Unknown | — | — | — |
NCT03517618CT.gov TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC | — | Completed | — | — | — |
NCT02688023CT.gov Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer | — | Unknown | — | — | — |
NCT01193452CT.gov S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer | — | Unknown | — | — | — |
NCT01929421CT.gov A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer. | — | Completed | — | — | — |
NCT01110941CT.gov Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China | — | Completed | — | — | — |
NCT00891332CT.gov Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00721916CT.gov Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT00677443CT.gov Study of S-1 and Oxaliplatin (SOX) Versus Capecitabine and Oxaliplatin (COX) in Patients With Advanced Colorectal Cancer | — | Completed | — | — | — |
NCT00569790CT.gov Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00569699CT.gov Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC) | — | Completed | — | — | — |
NCT00569335CT.gov Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer | — | Completed | — | — | — |
NCT00524706CT.gov Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| S-1 (this asset) | Tao Zhang | P3 | B · 62 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
| Panitumumab | MSPU des 3 Provinces | P3 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for S-1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P4 | BB · 68 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | BB · 65 |
| Gastric Neoplasm | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. S-1 in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/s-1-colorectal-cancer-106685
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →